Shanghai Bintie Biotechnology

Immuxell is a biotechnology company specializing in the development of bispecific T Cell Engagers to combat cancer. Utilizing its proprietary TETHER platform, Immuxell creates off-the-shelf biologics that redirect and activate the body's own T cell immune response towards cancer cells expressing specific oncogenic driver targets. The company's advanced affinity maturation capabilities and biotherapeutic technologies produce T Cell Engagers with balanced CD3 binders and extended half-life, aiming for sustained T cell responses against solid tumors. Immuxell serves patients with advanced solid tumors, leveraging scientific advancements in gene editing, synthetic biology, and cell therapies to deliver potentially curative treatments. The business operates in the oncology therapeutics market, primarily targeting oncogenic driver mutations like KRAS, which are crucial for tumor growth and maintenance. Immuxell generates revenue through the development and commercialization of its proprietary therapies, as well as potential partnerships and licensing agreements.

Keywords: bispecific T Cell Engagers, TETHER platform, oncogenic driver mutations, solid tumors, affinity maturation, CD3 binders, extended half-life, gene editing, synthetic biology, immunotherapy.